Trends
Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.
Bereits Mitglied? Einloggen
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Mehr anzeigen
Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.54 | -14.2197599261 | 10.83 | 10.8554 | 9.21 | 434440 | 9.73144411 | CS |
4 | -1.97 | -17.4955595027 | 11.26 | 11.87 | 9.21 | 336066 | 10.45014898 | CS |
12 | -2.96 | -24.1632653061 | 12.25 | 12.68 | 9.21 | 371596 | 10.70708699 | CS |
26 | -4.93 | -34.6694796062 | 14.22 | 14.57 | 9.21 | 475700 | 11.95228234 | CS |
52 | -9.03 | -49.2903930131 | 18.32 | 20.7 | 9.21 | 497282 | 13.97323447 | CS |
156 | 3.37 | 56.9256756757 | 5.92 | 24.13 | 4.85 | 317159 | 13.95435759 | CS |
260 | -16.71 | -64.2692307692 | 26 | 30.89 | 4.85 | 255061 | 15.33352356 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen